Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.
Normunity has raised $75.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
Normunity's investors include HSG, Canaan Partners, Samsara BioCapital, Connecticut Innovations, OUP (Osage University Partners).
Normunity is headquartered in New Haven, United States.
Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.
Normunity is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Normunity — Funding & Investors." VCBacked, January 13, 2025, https://www.vcbacked.co/company/normunity. Accessed July 20, 2026.
VCBacked. (2025). Normunity — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/normunity
{{cite web |title=Normunity — Funding & Investors |url=https://www.vcbacked.co/company/normunity |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated